Haynes Lab: Difference between revisions
From OpenWetWare
Jump to navigationJump to search
No edit summary |
Jan Simper (talk | contribs) No edit summary |
||
| (One intermediate revision by one other user not shown) | |||
| Line 19: | Line 19: | ||
'''Synthetic chromatin for cell differentiation''' | '''Synthetic chromatin for cell differentiation''' | ||
* David Barclay (FURI & SynBERC, BS) - pancreas, Jan Simper (FURI, BS) - cardiac | * David Barclay (FURI & SynBERC, BS) - pancreas, Jan Simper (FURI, BS) - cardiac | ||
* Description: Testing the "PcTF" synthetic chromatin protein/ transcription activator described in [http://www.ncbi.nlm.nih.gov/pubmed/21669865 Haynes & Silver 2011] to determine its ability to alter the phenotypes of healthy cells, such as pancreas | * Description: Testing the "PcTF" synthetic chromatin protein/transcription activator described in [http://www.ncbi.nlm.nih.gov/pubmed/21669865 Haynes & Silver 2011] to determine its ability to alter the phenotypes of healthy cells, such as cell fate switching from alpha cells to beta cells in the pancreas to treat diabetes or the growing of programmable "organoids" from iPS cells. | ||
| Line 41: | Line 41: | ||
* [http://openwetware.org/wiki/Haynes_Lab:Notebook/SynBERC_Scholars_2013 Alfonso & Zazu] | * [http://openwetware.org/wiki/Haynes_Lab:Notebook/SynBERC_Scholars_2013 Alfonso & Zazu] | ||
* [http://openwetware.org/wiki/User:Behzad_Damadzadeh/Notebook/PcTF_Subcloning_in_E-coli Behzad] | * [http://openwetware.org/wiki/User:Behzad_Damadzadeh/Notebook/PcTF_Subcloning_in_E-coli Behzad] | ||
* [http://openwetware.org/wiki/Haynes_Lab:Notebook/RNA-seq_of_PcTF_Transfected_U2OS_%26_SK-N-SH_cell_lines Ben] | |||
* [http://openwetware.org/wiki/Haynes_Lab:Notebook/Engineering_PC-TFs Cameron] | * [http://openwetware.org/wiki/Haynes_Lab:Notebook/Engineering_PC-TFs Cameron] | ||
* [http://openwetware.org/wiki/User:David_Barclay/Notebook David Barclay] | * [http://openwetware.org/wiki/User:David_Barclay/Notebook David Barclay] | ||
Revision as of 09:46, 11 December 2014
Our group uses synthetic, systems, and quantitative biology to engineer useful gene and protein-based biological devices and to deepen our understanding of molecular cell biology. We operate biological devices primarily in human/ mammalian cells. Accelerating the pace of therapeutic technologies (such as tissue regeneration and customizable protein-based drugs) via modular design is the grand challenge that shapes our research plans.
CURRENT SYNTHETIC BIOMEDICAL ENGINEERING PROJECTS
Synthetic chromatin for cell differentiation
- David Barclay (FURI & SynBERC, BS) - pancreas, Jan Simper (FURI, BS) - cardiac
- Description: Testing the "PcTF" synthetic chromatin protein/transcription activator described in Haynes & Silver 2011 to determine its ability to alter the phenotypes of healthy cells, such as cell fate switching from alpha cells to beta cells in the pancreas to treat diabetes or the growing of programmable "organoids" from iPS cells.
Editing synthetic genes using CRISPR
- René Davis (Biological Design, PhD)
- Description: Characterizing chromatin/CRISPR interactions. Re-engineering synthetic gene circuits in human cells using CRISPR.
Engineering synthetic chromatin transcription factors
- Cameron Gardner (FURI, BS)
- Description: Building and testing re-engineered versions of the "PcTF" synthetic chromatin protein/ transcription activator described in Haynes & Silver 2011.
Microbial communication with synthetic quorum sensing
- René Davis (Biological Design, PhD), Ryan Muller (SOLUR, BS)
- Description: Characterizing cross-talk between decoupled cell-cell communication systems from bacteria.
Lab Notebooks - Active
Lab Notebooks - Archived
